Juan Tong1, Zimin Sun1, Huilan Liu2, Liangquan Geng2, Changcheng Zheng1, Baolin Tang2, Kaidi Song2, Wen Yao2, Xin Liu2. 1. Shandong University, School of Medicine, Jinan 250012, China; ; Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, China. 2. Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, China.
Abstract
OBJECTIVE: This retrospective study examined risk factors for cytomegalovirus (CMV) infection after umbilical cord blood transplantation (UCBT) and the impact of CMV infection on patient survival. METHODS: In all 176 patients, plasma CMV DNA was negative prior to the transplantation, and examined twice a week for 100 d, and then once weekly for additional 300 d. Preemptive antiviral therapy (ganciclovir or foscarnet) was started in patients with >1,000/mL copies of CMV DNA but no full-blown CMV disease, and was discontinued upon two consecutive negative reports of blood CMV DNA test. The survival and risk factors for CMV infection or disease were examined using logistic regression. RESULTS: CMV infection developed in 71% (125/176) of the patients, with a median onset of 32 d. Four patients (2.3%) developed CMV disease. Neither the 5-year overall survival (OS) nor event-free survival (EFS) differed significantly in infected patients vs. those with no infection (59.4% vs. 64.8%, P=0.194; 53.4% vs. 59.1%, P=0.226). A stepwise multivariate analysis indicated an association of CMV infection with age, high-dose glucocorticoids, the number of transplanted CD34(+) cells, and the number of platelet transfusion, but not with gender, the conditioning regimen, and the day of neutrophil recovery and chronic graft-versus-host disease (cGVHD). CONCLUSIONS: CMV infection is very common after UCBT, but does not seem to affect long-term survival with preemptive antiviral treatment.
OBJECTIVE: This retrospective study examined risk factors for cytomegalovirus (CMV) infection after umbilical cord blood transplantation (UCBT) and the impact of CMV infection on patient survival. METHODS: In all 176 patients, plasma CMV DNA was negative prior to the transplantation, and examined twice a week for 100 d, and then once weekly for additional 300 d. Preemptive antiviral therapy (ganciclovir or foscarnet) was started in patients with >1,000/mL copies of CMV DNA but no full-blown CMV disease, and was discontinued upon two consecutive negative reports of blood CMV DNA test. The survival and risk factors for CMV infection or disease were examined using logistic regression. RESULTS:CMV infection developed in 71% (125/176) of the patients, with a median onset of 32 d. Four patients (2.3%) developed CMV disease. Neither the 5-year overall survival (OS) nor event-free survival (EFS) differed significantly in infectedpatients vs. those with no infection (59.4% vs. 64.8%, P=0.194; 53.4% vs. 59.1%, P=0.226). A stepwise multivariate analysis indicated an association of CMV infection with age, high-dose glucocorticoids, the number of transplanted CD34(+) cells, and the number of platelet transfusion, but not with gender, the conditioning regimen, and the day of neutrophil recovery and chronic graft-versus-host disease (cGVHD). CONCLUSIONS:CMV infection is very common after UCBT, but does not seem to affect long-term survival with preemptive antiviral treatment.
Authors: Suzanne M McGoldrick; Marie E Bleakley; Abraham Guerrero; Cameron J Turtle; Tori N Yamamoto; Shalini E Pereira; Colleen S Delaney; Stanley R Riddell Journal: Blood Date: 2013-02-14 Impact factor: 22.113
Authors: Jonathan A Gutman; Wendy Leisenring; Frederick R Appelbaum; Ann E Woolfrey; Colleen Delaney Journal: Biol Blood Marrow Transplant Date: 2009-09 Impact factor: 5.742
Authors: Angela R Smith; K Scott Baker; Todd E Defor; Michael R Verneris; John E Wagner; Margaret L Macmillan Journal: Biol Blood Marrow Transplant Date: 2009-09 Impact factor: 5.742
Authors: Ahmet H Elmaagacli; Nina K Steckel; Michael Koldehoff; Yael Hegerfeldt; Rudolf Trenschel; Markus Ditschkowski; Sandra Christoph; Tanja Gromke; Lambros Kordelas; Hellmut D Ottinger; Rudolf S Ross; Peter A Horn; Susanne Schnittger; Dietrich W Beelen Journal: Blood Date: 2011-05-03 Impact factor: 22.113
Authors: R Ursu; J Doridam; E Chaugne; H Zannou; C Belin; S Cuzzubbo; L Sirven-Villaros; S Brichler; C Levy-Piedbois; A F Carpentier Journal: J Neurovirol Date: 2021-01-06 Impact factor: 2.643
Authors: Laura Diaz; Joaquin Rosales; Fernando Rosso; Maria Rosales; Mayra Estacio; Eliana Manzi; Francisco Javier Jaramillo Journal: Hematol Transfus Cell Ther Date: 2019-02-22